HepaRegeniX, a clinical-stage company developing therapies for liver diseases, completed a €21.5 million financing round with Wellington Partners. The funding will support the ongoing Phase Ib trial and advance the Phase IIa clinical trial for HRX-215, their lead candidate for liver regeneration. HRX-215 is a first-in-class, oral small molecule inhibitor targeting MKK4, a key regulator of liver regeneration.
This investment underscores the growing interest in novel liver disease treatments and recognizes the potential of HRX-215. The successful completion of this funding round allows HepaRegeniX to accelerate clinical development, potentially bringing a much-needed therapy to patients faster. The focus on MKK4 inhibition represents a unique approach to stimulating liver regeneration, which could be transformative for patients facing liver resection, transplantation, or chronic liver diseases. This approach offers a potential alternative to current treatments, addressing a significant unmet medical need.
HepaRegeniX secured €21.5 million, bringing the total for the round to over €40M, enabling the advancement of HRX-215 through Phase Ib/IIa trials. Preclinical studies have shown promising results in both healthy and diseased livers in animal models. The Phase I trial in healthy participants confirmed a favorable safety and pharmacokinetic profile. Wellington Partners joins existing investors including Vesalius Biocapital IV, Novo Holdings A/S, Boehringer Ingelheim Venture Fund, and others.
This funding milestone allows HepaRegeniX to gather crucial clinical data for HRX-215. Positive results from the upcoming trials could significantly impact the landscape of liver disease treatment, offering new hope for patients and potentially leading to partnerships or further investments. The progress of HRX-215 may also stimulate further research into MKK4 inhibition and its application in other therapeutic areas.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
